title: Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole.
abstract: OBJECTIVE
  To evaluate the spontaneous regression curve of serum human chorionic gonadotropin (hCG) in patients with an uneventful course after evacuation of hydatidiform mole and to compare the criteria for initiating chemotherapy in patients after evacuation of mole.
  
  
  METHODS
  From 1986 to 2001, 608 patients were followed at our department after evacuation of mole. The spontaneous regression curves of serum hCG in 432 patients with an uneventful course were established.
  
  
  RESULTS
  After evacuation of mole, the titers of serum hCG decreased constantly, and 90% of patients with an uneventful course were within normal range within 16 weeks. In 432 patients with an uneventful course, the upper 95% confidence limit of serum hCG at 5, 8 and 20 weeks was 753.7, 422.9 and 14.8 mIU/ml, respectively. Moreover, 39 (9.0%) and 15 patients (3.5%) with an uneventful course might have been diagnosed with gestational trophoblastic tumor and received needless chemotherapy based on the normal regression curve established by the Japan Society of Obstetrics and Gynecology or the US criteria of 4 consecutive plateauing or rising hCG values, respectively.
  
  
  CONCLUSIONS
  Our more selective criteria for initiating chemotherapy in patients after evacuation of mole, i.e. hCG of 10,000 mIU/ml at 5 weeks, 1,000 mIU/ml at 8 weeks and nondetectable levels at 24 weeks after evacuation of mole, may be safe and acceptable in the management of patients after evacuation of mole.
authors: Department of Reproductive Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. hmatsui@med.m.chiba-u.ac.jp
authors: Hideo
authors: H
authors: Matsui
authors: Yoshinori
authors: Y
authors: Iitsuka
authors: Koji
authors: K
authors: Yamazawa
authors: Naotake
authors: N
authors: Tanaka
authors: Akira
authors: A
authors: Mitsuhashi
authors: Katsuyoshi
authors: K
authors: Seki
authors: Souei
authors: S
authors: Sekiya
mesh_terms: D006063:Chorionic Gonadotropin / Q000097:blood*; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D006828:Hydatidiform Mole / Q000188:drug therapy* / Q000601:surgery*; D007124:Immunoenzyme Techniques; D011247:Pregnancy; D011863:Radioimmunoassay; D013997:Time Factors
chemical_list: D006063:Chorionic Gonadotropin